Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tyme Technologies, Inc.

0.3107
0.0000
Volume:- -
Turnover:- -
Market Cap:53.50M
PE:-2.11
High:0.3107
Open:0.3107
Low:0.3107
Close:0.3107
52wk High:1.14
52wk Low:0.2187
Shares:172.21M
Float Shares:101.55M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1472
EPS(LYR):-0.1372
ROE:-28.36%
ROA:-15.71%
PB:0.72
PE(LYR):-2.26

Loading ...

Company Profile

Company Name:
Tyme Technologies, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; NYU School of Medicine to examine multiple aspects of SM-88 mechanisms; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.